CGCI: Cancer Genome Characterization Initiative

CGCI supports research to comprehensively catalog the genomic alterations in adult and pediatric cancers. The research community can use CGCI data to gain insight into the underlying mechanisms of these cancers and identify potential therapeutic targets.

Cancer Genome Characterization Initiative banner shows logo, genomics cartoon, and a boy with his dad. Links to program landing page.

News & Publications

CAT scan image of GBM
April 03, 2017

Glioblastoma (GBM) is the most common primary brain tumor and has a dismal prognosis. Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently observed in numerous human cancers including GBM. Phosphoinositide 3-kinase enhancer (PIKE) is a group of GTP-...

Projects

Burkitt Lymphoma

The goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to explore potential genetic changes in patients with Burkitt lymphoma (BL)Opens in a New Tab that could lead to better prevention, detection, and treatment of this rare and aggressive cancer.

HIV-Associated Cancers

The Office of Cancer Genomics (OCG)Opens in a New Tab, along with the Office of HIV and AIDS Malignancies (OHAM)Opens in a New Tab, initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients.

Medulloblastoma

CGCI developed the Medulloblastoma Project to apply newly emerging genomic methods towards the discovery of novel genetic alterations in medulloblastoma (MB)Opens in a New Tab.

Non-Hodgkin Lymphoma

CGCI initiated the Non-Hodgkin Lymphoma Project to elucidate the mutation spectrums of the two most abundant forms of non-Hodgkin lymphoma (NHL)Opens in a New Tab: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

Last updated: March 17, 2017